Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-11-16
Based on 577 first isolates · SURG · Skin / wound infection · 2024-11-17 → 2025-11-16
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 56 % (52 %–60 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (98 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (14 %), Escherichia coli (12 %), Proteus mirabilis (8 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
56 %
52 %
n = 23
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
44 %
39 %
n = 23
meropenem MEM
trend · Pseudomonas aeruginosa reserve
43 %
43 %
n = 23
40 %
39 %
n = 23
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
40 %
30 %
n = 23
ceftriaxone CRO
trend · Escherichia coli
27 %
13 %
n = 23
25 %
13 %
n = 23
21 %
17 %
n = 23
11 %
17 %
n = 23
mecillinam MEC
not for this site
0 %
0 %
n = 23
trimethoprim TMP
not for this site
0 %
0 %
n = 23
nitrofurantoin NIT
not for this site
0 %
0 %
n = 23

Most likely organisms for this profile

Staphylococcus aureus
46 %
Pseudomonas aeruginosa
14 %
Escherichia coli
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
8 %
Citrobacter freundii
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.